RecruitingTumor Pancreas
Evaluate the Safety and Efficacy of BGT007H Cell Therapy in Patients With Relapsed/Refractory Pancreatic Cancer
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary objective of this study is to evaluate the safety and tolerability of BGT007H cell therapy in patients with recurrent/refractory pancreatic cancer.
Sponsor: RenJi Hospital
You may qualify if…
- ✓ 1. voluntarily sign an informed consent form in writing.
- ✓ 2. Age ≥18 years and ≤75 years, both male and female are eligible.
- ✓ 3. Expected survival ≥ 3 months.
- ✓ 4. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
- ✓ 5. Can provide pathological paraffin section detection targets (within 3 years prior to signing the informed consent form).
- ✓ 6. According to the RECIST v1.1 criteria for the evaluation of solid tumors, there must be at least one measurable lesion, and the longest diameter of the lesions assessed by CT or MRI at baseline must be ≥ 10 mm (excluding lymph nodes, for which the short diameter must be ≥ 15 mm).
- ✓ 7. Advanced pancreatic cancer confirmed by histology or cytology, with progression after second-line or later standard treatment, or intolerance to standard treatment, or no standard treatment available. The definition of intolerance: according to CTCAE v5.0, grade ≥IV hematological toxicity or grade ≥III non-hematological toxicity or grade ≥II damage to major organs such as heart, liver, and kidney occurred during treatment. The definition of treatment failure: disease progression (PD) during treatment or recurrence after treatment (including postoperative recurrence).
- ✓ 8. Apheresis or venous blood collection venous access can be established, and there are no other contraindications to blood cell separation.
You may not qualify if…
- ✕ 1. Has active central nervous system (CNS) metastasis (except for those treated and stable).
- ✕ 2. HIV positive, HBsAg positive with positive Hepatitis B virus (HBV) DNA copy number (greater than the lower limit of detection), Hepatitis C virus (HCV) antibody positive and HCV RNA positive, syphilis non-treponemal antibody (RPR or TRUST) positive.
- ✕ 3. Has a mental or psychological disorder that cannot cooperate with treatment and efficacy evaluation.
- ✕ 4. Subjects with severe autoimmune diseases who have been long-term users of immunosuppressants.
- ✕ 5. Within 14 days before enrollment, there is an active infection or uncontrollable infection that requires systemic treatment.
- ✕ 6. Any unstable systemic diseases (including but not limited to): active infection (except for localized infection); unstable angina; cerebral ischemia or cerebral stroke (within 6 months of screening); myocardial infarction (within 6 months of screening); congestive heart failure (New York Heart Association (NYHA) class ≥ III); severe arrhythmia requiring medication treatment; heart disease requiring treatment or uncontrolled hypertension after treatment (blood pressure \> 160 mmHg/100 mmHg).
- ✕ 7. Combined with dysfunction of important organs such as lungs, brain, and kidneys.
- ✕ 8. Within 4 weeks before receiving cell therapy, the subject has undergone major surgery or serious trauma, or is expected to undergo major surgery during the study period.
Source: ClinicalTrials.gov · NCT06478225 · last updated 2024-06-27